Cardiometabolic Syndrome Presentation PDF Slides
Presentation: RECENT PARADIGM SHIFTS IN THE MANAGEMENT OF DIABETES AND ITS COMPLICATIONS
With the introduction of new classes of medications and changes to diabetes devices and technology, there is a paradigm shift in diabetes management in both type 1 and type 2 diabetes. The blockbuster drugs SGLT2i, finerinone and incretin therapies will likely the reduce progression of diabetic kidney disease and cardiometabolic complications. Much of the trial data comes from people with type 2 diabetes and there is a great need for more clinical trial activity in people with type 1 diabetes. Continuous glucose monitoring devices are painless, provide information on glucose patterns and are convenient. Coupled with hybrid closed insulin pump therapies, this technology will lead to reduced complications in in people with type 1 diabetes.
The Australian Centre for Accelerating Diabetes Innovation (ACADI) is “an innovation ecosystem” and is a virtual group of diabetes researchers, projects and platforms, organisations, people with lived experience and industry that are important for innovative discoveries in diabetes research. ACADI’s aim is to deliver novel interventions for timely diagnosis, prevention and treatment of diabetes and its complications.

